1Biochemistry Laboratory, LR12ES05 Nutrition-Functional Foods, and Vascular Health, Faculty of Medicine, University of Monastir, Tunisia
2Neurology & Neurophysiology Center, Austria
*Corresponding author:Sounira Mehri, Biochemistry Laboratory, LR12ES05 Nutrition-Functional Foods, and Vascular Health, Faculty of Medicine, University of Monastir, Tunisia
Submission: October 08, 2026;Published: October 29, 2026
ISSN : 2578-0263Volume7 Issue2
Obesity is a multifactorial metabolic disorder characterized by excessive adipose tissue and profound disturbances in lipid metabolism. This review provides a comprehensive overview of current evidence on Fatty Acid (FA) profiles and estimated desaturase activities in individuals with obesity, with emphasis on Stearoyl-CoA Desaturase-1 (SCD1), Delta-5 Desaturase (D5D), and Delta-6 Desaturase (D6D) as potential biomarkers of metabolic dysfunction integrating evidence from human observational studies, experimental models, and genetic investigations. A comprehensive evaluation of FA composition, desaturase enzyme pathways, and their associations with metabolic complications in obesity. We examined biochemical regulation, methodological considerations, genetic influences (including FADS polymorphisms), and the impact of nutritional and pharmacological interventions. Qualitative alterations in FA composition and desaturase activity are increasingly recognized as important determinants of obesity-associated metabolic dysfunction. individuals with obesity frequently exhibit altered FA profiles and estimated desaturase activities. Evidence from human, experimental, and genetic studies supports mechanistic links between desaturase dysregulation, lipotoxicity, inflammation, and cardiometabolic risk. However, methodological heterogeneity, the indirect nature of estimated desaturase indices, population-specific genetic and dietary effects, and limited prospective validation represent important challenges. Altered FA profiles and desaturase indices are promising biomarkers for characterizing metabolic dysfunction in obesity. Future integration of lipidomic approaches with genomic, metabolic, and clinical parameters may improve identification of individuals at increased cardiometabolic risk and support personalized nutritional and therapeutic strategies. Prospective longitudinal and intervention studies remain essential to establish incremental predictive value, reproducibility, and clinical applicability before translation into routine practice.
Keywords:Obesity; Fatty acid; Biochemical pathways; Clinical associations; Methodological considerations; Therapeutic strategies
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in